Omnaris (ciclesonide nasal spray) / Sumitomo Pharma, Azurity Pharma - LARVOL DELTA

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison table: Some nasal sprays for seasonal allergic rhinitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation

The Rising Cost of Rhinologic Medications. (PubMed, Ann Allergy Asthma Immunol) - "The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations."

Journal • Allergy • Immunology • Otorhinolaryngology

Inhaled Ciclesonide for Outpatients With COVID19 (clinicaltrials.gov) - P2/3; N=215; Terminated; Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Active, not recruiting ➔ Terminated; could not meet target enrolment

Clinical • Trial termination • Infectious Disease • Novel Coronavirus Disease

Inhaled Ciclesonide for Outpatients With COVID19 (clinicaltrials.gov) - P2/3; N=215; Active, not recruiting; Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Recruiting ➔ Active, not recruiting; N=454 ➔ 215; Trial completion date: Mar 2021 ➔ Aug 2021; Trial primary completion date: Feb 2021 ➔ Jul 2021

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Nip it in the bud: New study will attack SARS-Cov2 where it multiplies (MUHC) - "...they started testing the efficiency of ciclesonide, an inhaled and nasal steroid drug....This placebo-controlled randomized trial will confirm if the administration of inhaled and nasal ciclesonide can reduce the severity of respiratory symptoms among mild cases of COVID-19 and potentially avoid the need for hospitalization and oxygen....The study enrolls adults diagnosed with COVID-19 fewer than 5 days prior to enrollment....Participants are randomly assigned the study drug or placebo in the form of an inhaler and nasal spray..."

Trial status • Infectious Disease • Novel Coronavirus Disease